Life Science News

RSS

Urgent call for long-term investment in antibiotic research

Antibiotic resistance is a global public health threat. Modern health systems rely on antibiotics to prevent and treat infections, and the need for new drugs is urgent.

23 Sep 2024

The role of CRISPR-Cas9 in combating mosquito-borne diseases

Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of insecticides, thus further increasing mosquito resistance and exposing the world to an elevated risk of mosquito-borne diseases.

23 Sep 2024

Enhanced TnpB protein offers new possibilities for gene editing

CRISPR-Cas is used broadly in research and medicine to edit, insert, delete or regulate genes in organisms. TnpB is an ancestor of this well-known "gene scissor" but is much smaller and thus easier to transport into cells.

23 Sep 2024

Key genetic factors linked to severe cholera symptoms discovered

Experts have used a cutting-edge computational approach to discover the genetic factors that make the bacteria behind cholera so dangerous - which could be key to preventing this deadly disease.

23 Sep 2024

Study uncovers novel genetic variant associated with intellectual disability

Researchers at the Icahn School of Medicine at Mount Sinai have published a pivotal study in Nature Genetics (DOI: 10.1038/s41588-024-01917-1) that sheds light on a novel genetic variant associated with intellectual capacities and educational outcomes.

23 Sep 2024

AB ANALITICA partners in DECIDER project en

AB ANALITICA partners in DECIDER project to improve diagnostics and treatment of ovarian cancer with the help of AI – 15 million euros in funding from the EU

From AB ANALITICA 23 Sep 2024

AB ANALITICA x SNIBE partnership – July 22, 2024

AB ANALITICA and SNIBE are proud to announce a distribution partnership in Italy for SNIBE Molecision R8 platform, and both companies will focus on the development and commercialization of next-generation molecular tests on this platform.

From AB ANALITICA 23 Sep 2024

3DHISTECH launches the new flagship P480 2nd Generation, powered with polarization

3DHISTECH unveils its latest flagship product, the P480 2nd Gen. Leveraging a decade of research and diagnostic excellence established by the P480, the P480 2nd Gen introduces new features and incorporates notable enhancements to meet the evolving needs and exigencies of modern digitized laboratories.

From 3DHISTECH 23 Sep 2024

Seeing the unseen, together. 3DHISTECH and Barco at the 20th European Congress on Digital Pathology 2024

The ECDP 2024 event brings together experts, researchers, and industry leaders in the field of digital pathology. Join us from June 6th to June 8th in Vilnius, Lithuania, for an exciting collaboration that promises to advance research and innovation!

From 3DHISTECH 23 Sep 2024

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

From MaxCyte, Inc. 23 Sep 2024

Brain scans reveal link between SSRI use and cognitive function

Researchers have found that SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants have the potential to improve certain cognitive functions, such as verbal memory. They measured brain function in patients before and after taking the SSRI escitalopram and correlated this to a drop in the level of one of the serotonin receptors in the brain and to cognitive improvements during treatment.

22 Sep 2024

Dietary antigens reduce small intestine cancer by boosting immune T-cells

Study shows that dietary antigens can suppress small intestine carcinogenesis by activating T-cells through Peyer's patches. Adding bovine serum albumin (BSA) or ovalbumin (OVA) to antigen-free diets restored immune function and reduced tumor growth in mice.

22 Sep 2024

Scientists develop new method for relocating misplaced proteins

Cells are highly controlled spaces that rely on every protein being in the right place. Many diseases, including cancers and neurodegenerative disorders, are associated with misplaced proteins.

20 Sep 2024

New insights into lasso peptides offer promise for drug development

Lasso peptides are natural products made by bacteria. Their unusual lasso shape endows them with remarkable stability, protecting them from extreme conditions

20 Sep 2024

Fever enhances immune cell activity and induces mitochondrial stress

Fever temperatures rev up immune cell metabolism, proliferation and activity, but they also -; in a particular subset of T cells -; cause mitochondrial stress, DNA damage and cell death, Vanderbilt University Medical Center researchers have discovered.

20 Sep 2024

Virginia Tech researchers uncover bacterial infection mechanism

Virginia Tech researchers have learned how bacteria manipulate molecules to infect the host organism.

20 Sep 2024

STING protein plays new role in cellular stress clearance and survival

A protein called STING, previously shown to control a pathway that contributes to antiviral signaling, also plays an important role in cellular stress clearance and cell survival, according to a new paper published in Molecular Cell.

20 Sep 2024

Novel drug molecule offers hope for early Parkinson's disease treatment

A novel drug molecule could potentially lead to new treatments to prevent Parkinson's disease in younger patients, according to new research.

20 Sep 2024

UCLA develops largest collection of patient-derived organoids for sarcoma research

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.

20 Sep 2024

Nagi Bioscience launches exclusive Priority Access Program, bringing revolutionary SydLab™ One platform to five leading academic labs for C. elegans research

Nagi Bioscience, a pioneer Swiss company pioneer in cutting-edge laboratory technologies for alternative model organisms research, proudly announces the launch of its exclusive Priority Access Program, providing access to five leading academic laboratories to the first-of-its-kind SydLab™ One platform.

From Nagi Bioscience 20 Sep 2024